|
Title
|
|
|
|
Cells to the rescue : emerging cell-based treatment approaches for NMOSD and MOGAD
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Cell-based therapies are gaining momentum as promising treatments for rare neurological autoimmune diseases, including neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. The development of targeted cell therapies is hampered by the lack of adequate animal models that mirror the human disease. Most cell-based treatments, including HSCT, CAR-T cell, tolerogenic dendritic cell and mesenchymal stem cell treatment have entered early stage clinical trials or have been used as rescue treatment in treatment-refractory cases. The development of antigen-specific cell-based immunotherapies for autoimmune diseases is slowed down by the rarity of the diseases, the lack of surrogate outcomes and biomarkers that are able to predict long-term outcomes and/or therapy effectiveness as well as challenges in the manufacturing of cellular products. These challenges are likely to be overcome by future research. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
International journal of molecular sciences
| |
|
Publication
|
|
|
|
Basel
:
Mdpi
,
2021
| |
|
ISSN
|
|
|
|
1422-0067
1661-6596
| |
|
DOI
|
|
|
|
10.3390/IJMS22157925
| |
|
Volume/pages
|
|
|
|
22
:15
(2021)
, 19 p.
| |
|
Article Reference
|
|
|
|
7925
| |
|
ISI
|
|
|
|
000682007300001
| |
|
Pubmed ID
|
|
|
|
34360690
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|